Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) will report financial results for its first quarter ended June 30, 2026 on Thursday, August 6, 2026, before the market opens. Roivant Sciences (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that day, including a business update for Immunovant. Access details, webcast links, and the archived replay will be available in the “News & Events” section of Immunovant’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – IMVT
In the Jul 24 session, IMVT gained 0.10%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Earnings date notice | Neutral | -1.4% | Fourth-quarter results and business update were scheduled for May 20, 2026. |
| Jan 23 | Earnings date notice | Neutral | +2.3% | Third-quarter results and business update were scheduled for February 6, 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The two tag-matched earnings-date notices produced mixed 24-hour reactions, with one decline and one gain.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant (Nasdaq: ROIV). As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com